High allostatic load, which has been linked to an increased incidence of breast cancer and all-cause mortality, is more than twice as likely to occur in Black and Hispanic women in comparison to White women, according to mammography research presented at the American Society of Clinical Oncology (ASCO) conference.
Black and Hispanic women have a significantly increased likelihood of high allostatic load (AL) than White women, according to a new mammography study presented at the American Society of Clinical Oncology (ASCO) conference.
In a retrospective study involving 9,798 women (mean age of 57) with no personal history of breast cancer, researchers assessed screening mammography data with a convolutional neural network (CNN) model and calculated AL scores based upon cardiovascular, metabolic, renal, and immune system biometric data from EHRs. The study authors noted that high AL scores were scores above the median AL score of 3. Hispanic women comprised 36.1 percent of the cohort and 9.6 percent of the cohort were non-Hispanic Black women, according to the study.
In a new study presented at the American Society of Clinical Oncology (ASCO) conference, researchers found that non-Hispanic Black women and Hispanic women were over 2.6 times more likely and over 2.1 times more likely, respectively, than White women to have high allostatic load, which has been linked to an increased incidence of breast cancer and all-cause mortality. (Image courtesy of Adobe Stock.)
In comparison to non-Hispanic White women, the researchers found that non-Hispanic Black women and Hispanic women were over 2.6 times more likely and over 2.1 times more likely, respectively, to have high AL, which has been linked to an increased incidence of breast cancer and all-cause mortality.
“In this cohort of diverse women undergoing screening mammography, we observed a significant association between high AL and older age and Black and Hispanic race/ethnicity,” noted lead study author Sara Wallam, M.D., who is affiliated with the Columbia University Irving Medical Center in New York, N.Y., and colleagues.
However, the study authors also noted that high AL scores occurred in women with lower breast density and had no correlation to CNN risk scoring.
“(Mammographic density) was inversely associated with high AL, likely due to higher BMI, and CNN risk score was not associated with AL,” pointed out Wallam and colleagues. “Future studies should evaluate the association between novel breast radiomic features and genetic and hormonal biomarkers of breast cancer risk.”
(Editor’s note: For related content, see “What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk,” “Study of Mammography AI Software Notes 50 Percent Higher Likelihood of False-Positive Results for Black Women” and “Abbreviated MRI and Contrast-Enhanced Mammography Provide Fourfold Higher Cancer Detection than Breast Ultrasound.”)
Reference
1. Wallam S, Ro V, McGuinness J, Ha R, Crew K. Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography. Presented at the American Society of Clinical Oncology (ASCO) conference, May 30-June 3, Chicago. Available at: https://meetings.asco.org/abstracts-presentations/248148 .
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.